WOSU: Could Mike DeWine's re-election bid be doomed by fellow Republicans?
UC political scientist David Niven’s gives opinion on DeWine’s chances in 2022
Ohio Gov. Mike DeWine may have a fight on his hands if he decides to run for the office again in 2022, experts say.
"I do think he is in trouble,'' said David Niven, professor of political science at the University of Cincinnati. "Mainly because of the degree to which the firmament beneath his feet has changed. Ohio Republicans are clearly part of the party of Trump."
Niven told WOSU that DeWine’s best chances to win his own party over are to do so in a crowded field of Republican contenders, or the long-time politician could to retire since he will be age 75 when the race takes place.
Featured image at top of Ohio Gov. Mike DeWine speaking at the Ohio Statehouse. Photo/Greenlees/AP/Dayton Daily News Pool.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
WLWT: Tips to fight off bad allergy symptoms
April 18, 2024
The University of Cincinnati's Ahmad Sedaghat spoke with WLWT about how Cincinnati's geography tends to make allergy symptoms worse and tips to fight off those symptoms.
UC’s Ground Floor Makerspace births combat robots
April 17, 2024
In the heart of UC's 1819 Innovation Hub lies the Ground Floor Makerspace, an advanced and active hub of ingenuity where students, faculty and the community converge to bring their ideas to life. This includes being the birthplace of robots much like miniature race cars, combating fender to fender in an enclosed boxing ring. Combat robots like UC's Maximizer will again be fighting for first place in the National Havoc Robot League (NHRL) competition, slated for April 20.
Medscape: Skin adverse events rare after immunotherapy to treat...
April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.